111 results
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and, except as required by applicable law, we do not plan to publicly
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
harbor provisions of the Private Securities Litigation Reform Act of 1995 and, except as required by applicable law, we do not plan to publicly
8-K
EX-10.1
CRNX
Crinetics Pharmaceuticals Inc
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
that the FDA or any governmental entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding
8-K
EX-99.1
5afqva7rkimt hd
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.2
otd1gwx2hmt gyx0bfqs
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
lvom1y9p1wt8 ew
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
8-K
EX-1.1
xt4rg7i8
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
424B5
c0h z8wp0
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
8r93u
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
EX-99.2
gan1d75kv7g0ylaor
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
jcv01
28 Nov 22
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
8:32am